ANGPTL8 protein-truncating variant associated with lower serum triglycerides and risk of coronary disease

Protein-truncating variants (PTVs) affecting dyslipidemia risk may point to therapeutic targets for cardiometabolic disease. Our objective was to identify PTVs that were associated with both lipid levels and the risk of coronary artery disease (CAD) or type 2 diabetes (T2D) and assess their possible...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:PLoS genetics Ročník 17; číslo 4; s. e1009501
Hlavní autoři: Helkkula, Pyry, Kiiskinen, Tuomo, Havulinna, Aki S., Karjalainen, Juha, Koskinen, Seppo, Salomaa, Veikko, Daly, Mark J., Palotie, Aarno, Surakka, Ida, Ripatti, Samuli
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States Public Library of Science 28.04.2021
Public Library of Science (PLoS)
Témata:
Analysis
Biobanks
Biology and Life Sciences
Cardiovascular disease
Cholesterol
Coronary heart disease
Coronary vessels
Diabetes
Drug delivery
Drugs
Dyslipidemia
Genetic aspects
Genomes
Heart diseases
Identification and classification
Lipids
Low density lipoprotein
Medicine and Health Sciences
Metabolic disorders
People and Places
Phenotypes
Population
Proteins
Risk factors
Side effects
Statins
Triglycerides
Finland
United Kingdom > UK
ISSN:1553-7404, 1553-7390, 1553-7404
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Protein-truncating variants (PTVs) affecting dyslipidemia risk may point to therapeutic targets for cardiometabolic disease. Our objective was to identify PTVs that were associated with both lipid levels and the risk of coronary artery disease (CAD) or type 2 diabetes (T2D) and assess their possible associations with risks of other diseases. To achieve this aim, we leveraged the enrichment of PTVs in the Finnish population and tested the association of low-frequency PTVs in 1,209 genes with serum lipid levels in the Finrisk Study (n = 23,435). We then tested which of the lipid-associated PTVs were also associated with the risks of T2D or CAD, as well as 2,683 disease endpoints curated in the FinnGen Study (n = 218,792). Two PTVs were associated with both lipid levels and the risk of CAD or T2D: triglyceride-lowering variants in ANGPTL8 (-24.0[-30.4 to -16.9] mg/dL per rs760351239-T allele, P = 3.4 × 10 −9 ) and ANGPTL4 (-14.4[-18.6 to -9.8] mg/dL per rs746226153-G allele, P = 4.3 × 10 −9 ). The risk of T2D was lower in carriers of the ANGPTL4 PTV (OR = 0.70[0.60–0.81], P = 2.2 × 10 −6 ) than noncarriers. The odds of CAD were 47% lower in carriers of a PTV in ANGPTL8 (OR = 0.53[0.37–0.76], P = 4.5 × 10 −4 ) than noncarriers. Finally, the phenome-wide scan of the ANGPTL8 PTV showed that the ANGPTL8 PTV carriers were less likely to use statin therapy (68,782 cases, OR = 0.52[0.40–0.68], P = 1.7 × 10 −6 ) compared to noncarriers. Our findings provide genetic evidence of potential long-term efficacy and safety of therapeutic targeting of dyslipidemias.
Bibliografie:new_version
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Membership of the FinnGen is listed in the S1 Text.
I have read the journal’s policy and the authors of this manuscript have the following competing interests: V.S. has consulted for Novo Nordisk and Sanofi and received honoraria from these companies (unrelated to the present study). He also has ongoing research collaboration with Bayer Ltd. (unrelated to the present study). A.P. is a member of the Pfizer Genetics Scientific Advisory Panel. The remaining authors declared no relevant competing interests.
ISSN:1553-7404
1553-7390
1553-7404
DOI:10.1371/journal.pgen.1009501